Correlation Between Vitrolife and Lipigon Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Vitrolife and Lipigon Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vitrolife and Lipigon Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Vitrolife AB and Lipigon Pharmaceuticals AB, you can compare the effects of market volatilities on Vitrolife and Lipigon Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vitrolife with a short position of Lipigon Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vitrolife and Lipigon Pharmaceuticals.

Diversification Opportunities for Vitrolife and Lipigon Pharmaceuticals

0.64

Correlation Coefficient

Vitrolife  Lipigon Pharmaceuticals

Poor diversification

The 3 months correlation between Vitrolife and Lipigon is 0.64. Overlapping area represents the amount of risk that can be diversified away by holding Vitrolife AB and Lipigon Pharmaceuticals AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lipigon Pharmaceuticals and Vitrolife is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vitrolife AB are associated (or correlated) with Lipigon Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lipigon Pharmaceuticals has no effect on the direction of Vitrolife i.e., Vitrolife and Lipigon Pharmaceuticals go up and down completely randomly.

Pair Corralation between Vitrolife and Lipigon Pharmaceuticals

Assuming the 90 days trading horizon Vitrolife AB is expected to under-perform the Lipigon Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Vitrolife AB is 3.9 times less risky than Lipigon Pharmaceuticals. The stock trades about -0.11 of its potential returns per unit of risk. The Lipigon Pharmaceuticals AB is currently generating about -0.02 of returns per unit of risk over similar time horizon. If you would invest  25.00  in Lipigon Pharmaceuticals AB on September 14, 2024 and sell it today you would lose (6.00) from holding Lipigon Pharmaceuticals AB or give up 24.0% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Vitrolife AB  vs.  Lipigon Pharmaceuticals AB

Vitrolife AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Vitrolife AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Lipigon Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Lipigon Pharmaceuticals AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Pair Trading with Vitrolife and Lipigon Pharmaceuticals

The main advantage of trading using opposite Vitrolife and Lipigon Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vitrolife position performs unexpectedly, Lipigon Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipigon Pharmaceuticals will offset losses from the drop in Lipigon Pharmaceuticals' long position.

The idea behind Vitrolife AB and Lipigon Pharmaceuticals AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.